Module 1: HIV Management in Primary Care: Foundations Course
This course is available for purchase as part of a package of courses:
Time to Complete
April 20, 2018
April 20, 2019
This is Module 1 in the HealthHIV HIV Primary Care Training and Certificate Program.
0.75 / AMA PRA Category 1 CreditTM
This activity is jointly provided by Postgraduate Institute for Medicine and HealthHIV.
This activity is not supported by educational grants.
The CDC estimates that 1,107,700 persons aged 13 years and older are living with HIV infection, including 166,000 (15%) who are unaware of their infection.1-3 Over the past decade, the number of people living with HIV has increased, while the annual number of new HIV infections has remained relatively stable. However, gay, bisexual, and other men who have sex with men (MSM), particularly young black/African American MSM, are most seriously affected by HIV. By race, blacks/African Americans face the most severe burden of HIV. According to the CDC, during a lifetime, risk of HIV infection overall is 1 in 99, for Black MSM is 1 in 2, and for Latino MSM is 1 in 4.
Current guidelines recommend screening all patients aged 15 to 65 for HIV. And it is now recommended that all patients with HIV receive antiretroviral therapy. In this activity you will learn how to how to effectively screen patients for HIV, manage initial considerations in HIV therapy, and gain a better understanding of the recommended guidelines for treating and managing HIV-infected patients.
Module 1 of HealthHIV’s HIV Primary Care Training and Certificate Program is designed to provide primary care providers and staff with an understanding of the epidemiology and natural history of HIV infection and the personal and public benefits of early treatment. Because HIV testing is the gateway to care, current recommendations for HIV testing will be discussed. This module is designed to be a foundation for the subsequent modules. _____________________________________
References 1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2015; vol. 27. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2016. Accessed 1/17/18. 2. CDC. Lifetime Risk of HIV Diagnosis. http://www.cdc.gov/nchhstp/newsroom/2016/croi-press-release-risk.html. Accessed 1/17/18. 3. CDC. 2016 Conference on Retroviruses and Opportunistic Infections.http://www.cdc.gov/nchhstp/newsroom/2016/croi-2016.html#Graphics. Accessed 1/17/18.
This activity has been designed to meet the educational needs of primary care physicians, and other allied healthcare professionals who treat and care for patients with HIV/AIDS.
After completing this activity, the participant will demonstrate the ability to:
Describe HIV surveillance data and the implications for individual and public health
Discuss the natural history of HIV disease and the implications for individual and public health
Explain the differences between risk-based and "opt-out" HIV screening and summarize the current recommendations
Utilize the most appropriate HIV test in different clinical settings
Summarize methods to reduce HIV transmission
Disclosure of Conflicts Of Interest
Postgraduate Institute of Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Donna E. Sweet, MD, MACP Professor of Medicine Director, Internal Medicine Education University of Kansas School of Medicine – Wichita Wichita, KS
Dr. Sweet discloses the following: Consulting Fees: Pfizer Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers bureau): Bristol-Myers Squibb and Gilead Contract Research: Merck
Planners and Managers Disclosure
The PIM planners and managers, Trace Hutchinson, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBS, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. The HealthHIV planners and managers Dana Cropper-Williams, Brian Hujdich, and Sibyl Wilmont and Michael Shankle, MPH, have nothing to disclose.
AMA PRA Category 1 Credit(s)TM
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HealthHIV. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the PDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the view of the planners. Please refer to the official prescribing information for each product for discussion of approval indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medication, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.